Specific disease or symptomsAcute myocardial infarction (AMI) is myocardial necrosis caused by acute coronary occlusion. Main manifestations: ? Typical chest pain (retrosternal crushing pain radiating to left shoulder/arm, not relieved by nitroglycerin)
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Meet the World Health Organization (WHO) 2008 revised diagnostic criteria for AMI (cardiac troponin >99th percentile of URL with dynamic changes, or new pathological Q waves, ST-segment elevation/depression, T-wave inversion on ECG); 2.Time from symptom onset to hospital admission <=72 hours; 3.Aged 35 to 75 years (inclusive); 4.Willing to participate and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe Liver Or Kidney Dysfunction: ALT/AST > 3× ULN, Or Serum Creatinine > 177 µmol/L, Or eGFR 38.5?, White Blood Cell Count > 12×10^9/L Or 50 mg/L, Active Tuberculosis, Viral Hepatitis (Positive HBV DNA Or HCV RNA), HIV Infection. 5. Recent Surgery Or Trauma: Major Surgery (Thoracotomy, Laparotomy, Craniotomy, Joint Replacement, Etc.) Or Severe Trauma (Multiple Fractures, Internal Organ Injury) Within The Past 3 Months. 6. Pregnancy Or Lactation: Positive Pregnancy Test (For Women Of Childbearing Potential) Or Currently Breastfeeding. 7. Psychiatric Disorders Or Cognitive Impairment: Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Dementia, Alzheimer's Disease, Etc., That Preclude Understanding Of The Study Or Completion Of Follow-Up. 8. History Of Substance Or Alcohol Abuse: Documented Drug Dependence Or Alcohol Abuse (Average Daily Alcohol Intake > 40 g For Males Or > 20 g For Females) Within The Past Year. 9. Incomplete Clinical Data Or Refusal To Provide Blood Sample: Missing Key Clinical Information (Symptom Onset Time, ECG, Cardiac Enzyme Profiles) In Medical Records, Or Refusal To Provide An Extra Blood Sample For Study Purposes. 10. Concurrent Participation In Other Interventional Clinical Trials: Participation In Any Other Drug, Device, Or Biologic Interventional Trial Within The Past 3 Months (Observational Studies Are Allowed).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRNA expression levels of ANXA3 and SOCS3, and their combined diagnostic performance (AUC, sensitivity, specificity).;Accuracy; | — |
Countries
China
Contacts
The First Hospital Of Jiaxing